



LAHIVE  
&  
COCKFIELD

L L P

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNKI  
RALPH A. LOREN  
GIULIO A. DeCONTI, JR.  
ANN LAMPERT HAMMITE  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DeANN FORAN SMITH  
PETER C. LAURO  
JEANNE M. DIGIORGIO  
DEBRA J. MILASINCIC, Ph.D.  
DAVID J. RIKKERS  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER

CYNTHIA L. KAN, Ph.D.  
MEGAN E. WILLIAMS, Ph.D.  
RICA NAND  
MICHAEL PHILLIPS  
LISA M. DIROCCO  
SENIOR COUNSEL  
JAMES E. COCKFIELD  
OF COUNSEL  
JEREMIAH LYNCH  
WILLIAM A. SCOFIELD, JR.  
PATENT AGENTS  
PETER S. STECHER  
THEODORE R. WEST  
SHAYNE Y. HUFF, Ph.D.  
HATHAWAY P. RUSSELL  
DANIEL B. KO

TECHNICAL SPECIALISTS  
MARIA LACCTORIPE ZACHARAKIS, Ph.D.  
CYNTHIA M. SOROS  
PETER W. DINI, Ph.D.  
EUIHOON LEE  
JENNIFER K. ROSENFIELD  
ALLAN TAMESHTIT, Ph.D.  
CATHERINE E. MCPHERSON  
ERIC F. WAGNER, Ph.D.  
SHAHID HASAN, Ph.D.  
JACOB G. WEINTRAUB  
JONATHAN M. SPARKS, Ph.D.  
CRISTIN E. HOWLEY, Ph.D.

\* Admitted in NY only  
\*\* Passed the Patent Bar Examination

GAC 1623  
#21  
MC

RECEIVED

September 17, 2001

SEP 21 2001

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Patent Application No.: 09/284,424  
Title: ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1 BETA  
CONVERTING ENZYME  
Inventor: Albrecht, Hans P. et al  
Filed: April 9, 1999  
Our Ref. No.: BBI-5037CPUS

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Supplemental Information Disclosure Statement (2 pgs.);
2. PTO Form 1449 (1 pg.);
3. Copies of References Cited in PTO Form 1449;
4. A copy of the Norwegian Search Report;
5. A copy of the International Search Report; and
6. This Acknowledgement Postcard.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any other necessary fees due in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

September 17, 2001

Date

Peter C. Lauro, Esq., Registration No. 32,360

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Peter C. Lauro, Esq.  
Registration No. 32,360  
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

SEP 21 2001

RECEIVED

In re the application of: Albrecht, Hans P. et al.

Group Art Unit: 1623

Serial No.: 09/284,424

Examiner: Maier, L.

Filed: April 9, 1999

For: ASPARTATE ESTER INHIBITORS OF  
INTERLEUKIN-1 BETA CONVERTING ENZYME

Attorney Docket No.: BBI-5037CPUS


Commissioner for Patents  
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

September 17, 2001

By:

  
Peter C. Lauro, Esq.

Reg. No. 32,360

Attorney for Applicants

Date of Signature and of Mail Deposit

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Applicants and their attorney have become aware of the following publications and information, cited in an International Search Report mailed July 16, 2001 during the prosecution of PCT/US00/25468 and a Norwegian Search Report mailed July 14, 2001 during the prosecution of patent application No. 199 1677 which correspond to the above referenced application. In accordance with 37 CFR §1.97, Applicants hereby submit these publications for the Examiner's consideration. These publications are cited on the enclosed PTO Form 1449, and a copy of the Report and each publication cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(e)(2), on information and belief, no individual associated with the filing or the prosecution of this application, as designated by §1.56(c), had any knowledge of the cited references more than three months prior to the filing of this statement.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP



Peter C. Lauro, Esq.  
Registration No. 32,360  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: September 17, 2001  
GAD/PCL/TRW/nim  
Enclosures